Analysts Project $28.9M Q1 Revenue for Outset Medical, Price Target of $9.00
Outset Medical will report Q1 2026 results on May 7 with revenue consensus of $28.90 million and an expected loss of $1.01 per share after Q4 sales beat estimates by 8.35%. Full-year 2026 revenue forecasts slipped to $126.77 million while 2027 estimates rose to $140.70 million and analysts set an average one-year target of $9.00.
1. Q1 2026 Earnings Preview
Outset Medical is scheduled to release its Q1 2026 earnings on May 7, with analysts forecasting $28.90 million in revenue and a loss of $1.01 per share. This follows a prior quarter where dialysis systems revenue showed growth and margins remained under pressure.
2. Analyst Estimate Revisions
Over the past 90 days, 2026 full-year revenue forecasts have marginally declined from $127.65 million to $126.77 million while 2027 estimates jumped from $128.03 million to $140.70 million. EPS projections improved slightly from a $4.02 loss to $4.01 loss for 2026 and from a $3.61 loss to $3.34 loss for 2027.
3. Q4 Results and Valuation Outlook
In Q4 2025, Outset Medical reported $28.87 million in revenue, beating expectations by 8.35%, and a loss of $1.09 per share, outperforming estimates by 2.68%. Following that release, shares fell over 16%, while analysts’ one-year price targets average $9.00 (95.7% upside) and brokerage consensus rates the stock as an Outperform.